B O O K - American College of Rheumatology

ACR/ARHP Poster Session B
Seibold 13 , 1 Brigham & Womens Hospital, Boston, MA, 2 German
Rheumatism Research Centre - Berlin, Berlin, Germany,
3
Institute of Clinical Pharmacology, Medical Faculty, University
of Dresden, Dresden, Germany, 4 Louisiana State University
Health Sciences Center - New Orleans, New Orleans, LA,
5
Mayo Clinic, Rochester, MN, 6 Medical University of Bialystok,
Bialystok, Poland, 7 National Jewish Health, Denver, CO, 8 Royal
Brompton Hospital and National Heart and Lung Institute,
London, United Kingdom, 9 Royal Free Hospital, London, United
Kingdom, 10 Stanford University; Palo Alto, Portola Valley, CA,
11
University Hospital Zurich, Zurich, Switzerland, 12 University
of California Los Angeles, Los Angeles, CA, 13 University of
Connecticut Health Center, Farmington, CT, 14 University of
Michigan, Ann Arbor, MI, 15 University of Michigan, Ann Arbor,
16
University of Pittsburgh, Pittsburgh, PA.
1213. Development of a Limited Scleroderma Cutaneous Activity and
Damage Index. Lorinda Chung 1 , Daniel E. Furst 5 , Paul Maranian 3 ,
Kait Arefiev 2 , Jeffrey Zwerner 2 , Dinesh Khanna 4 , Victoria P.
Werth 6 and David Fiorentino 2 , 1 Stanford Univ Medical Center,
Palo Alto, CA, 2 Stanford Univ Medical Center, 3 UCLA Medical
School, 4 University of California Los Angeles, Los Angeles,
CA, 5 University of California Los Angeles Medical School, Los
Angeles, CA, 6 University of Pennsylvania, Philadelphia, PA.
1214. Effect of Selective and Dual Endothelin Receptor Antagonists
(ERAs) on SSc and Control Endothelial Cells Apoptosis.
Yongqing Wang, Omar R. Kahaly and Bashar Kahaleh, University
of Toledo, Toledo, OH.
1215. Findings in Ocular Examination of Patients with Systemic
Sclerosis. Niki Tsifetaki 3 , Charalampos Papagoras 3 , Contantinos
A. Paschides 1 and Alexandros A. Drosos 2 , 1 Department of
Ophthalmology, Medical School, University of Ioannina,
Ioannina, Greece, 2 Ioannina Medical School, Ioannina, Greece,
3
Rheumatology Clinic, Department of Internal Medicine,
Medical School, University of Ioannina, Ioannina, Greece.
1216. Genetic and Clinical Correlates of Anti-Fibrillarin (U3-RNP)
Auto-Antibodies in African Americans with Systemic Sclerosis.
Roozbeh Sharif 2 , Marvin J. Fritzler 4 , John D. Reveille 3 , Shervin
Assassi 1 , Maureen D. Mayes 5 and Frank C. Arnett 6 , 1 Univ of
Texas Health Science, Houston, TX, 2 Univ of Texas Health
Science Center at Houston, Houston, TX, 3 Univ Texas Health Sci
Ctr, Houston, TX, 4 University of Calgary, Calgary, AB, Canada,
5
University of Texas-Houston, Houston, TX, 6 UT Medical School,
Houston, TX.
1217. Impact of Systemic Sclerosis on Occupational and Professional
Activity with Attention to Patients with Digital Ulcers. Alice
Berezne 3 , Raphaele Seror 2 , Sandrine Morell-Dubois 1 , Christelle
Nguyen 4 , Eric Hachulla 1 , Loic Guillevin 4 and Luc Mouthon 4 ,
1
Service de Medecine Interne, Centre de Reference Pour la
Sclerodermie Systemique, Hôpital Claude Huriez, Universite
Lille 2 , Lille, France, Metropolitan, 2 Université Paris Descartes,
Faculté de Médicine, Pôle de Médecine Interne, Centre de
Reference Pour les Vascularites Necrosantes et la Sclerodermie
Systemique, Hôpital Cochin, Assistance Publique-Hopitau,
3
Universite Paris Descartes, Faculte de Medicine, Pôle de
Medecine Interne, Centre de Reference Pour les Vascularites
Necrosantes et la Sclerodermie Systemique, Hôpital Cochin,
Assistance Publique-Hôpitaux de Paris, Paris, Fra, 4 Universite
Paris Descartes, Faculte de Medicine, Pole de Medecine Interne,
Centre de Reference Pour les Vascularites Necrosantes et la
Sclerodermie Systemique, Hopital Cochin, Assistance Publique-
Hopitaux de Paris (AP-HP), Paris, France, Metro.
1218. Is Surfactant D or CC-Chemokine Ligand 18 Biomarkers
for Interstitial Lung Disease in Systemic Sclerosis? Shervin
Assassi 2 , Julio Charles 3 , Frank C. Arnett 7 , Roozbeh Sharif 2 ,
Robert E. Lasky 3 , Emilio B. Gonzalez 5 , Hilda T. Draeger 4 , Terry
A. McNearney 1 , Sandeep K. Agarwal 2 , Ramana V. Gutala 3 , Rosa
M. Estrada-Y-Martin 3 and Maureen D. Mayes 6 , 1 Eli Lilly and
Co, Indianapolis, IN, 2 Univ of Texas Health Science Center at
Houston, Houston, TX, 3 Univ of Texas Health Science Center at
Houston, 4 Univ of Texas Health Science Center at San Antonio,
San Antonio, TX, 5 Univ of Texas Medical Branch Galveston,
Galveston, TX, 6 University of Texas-Houston, Houston, TX, 7 UT
Medical School, Houston, TX.
1219. Longitudinal Fatigue Severity Scale Scores Correlate with
Modifiable Psychosocial Variables in Early Systemic Sclerosis.
Astrud Lorraine Leyva 3 , Shervin Assassi 1 , Maureen D. Mayes 6 ,
Deepthi K. Nair 1 , Michael Fischbach 2 , Roozbeh Sharif 1 , John D.
Reveille 5 , Emilio B. Gonzalez 3 and Terry A. McNearney 4 , 1 Univ
of Texas Health Science Center Houston, Houston, TX, 2 Univ of
Texas Health Science Center San Antonio, San Antonio, TX, 3 Univ
of Texas Medical Branch, Galveston, TX, 4 Univ of Texas Medical
Branch; Currently at Eli Lilly and Co, Indianapolis, IN, 5 Univ
Texas Health Sci Ctr, Houston, TX, 6 University of Texas-Houston,
Houston, TX.
1220. Loss of Microvascular Response to Central Nervous Impulses
to Finger Pulp in Systemic Sclerosis. Tone Kristin Bergersen 2 ,
Anna-Maria Hoffmann-Vold 1 , Oivind Midtvet 2 , Jan Tore Gran 2 ,
Cato Mork 2 and Karin Toska 3 , 1 Oslo University Hospital, Oslo,
PO Box 4950 Nydalen, Norway, 2 Oslo University Hospital, Oslo,
Norway, 3 University of Oslo, PO Box 1103 Blindern, Norway.
1221. Lower Education as a Proxy for Socioeconomic Status Is? Not
Associated with Poor Outcomes in Systemic Sclerosis (SSc):
Data from a Large SSc Cohort (Canadian Scleroderma Research
Group). Samah Mansour 4 , Ashley Bonner 2 , Murray Baron 1 , Janet
E. Pope 3 and The CSRG, 1 Jewish General Hospital, Montreal, QC,
Canada, 2 McMaster University, 3 St Joseph Health Care London,
London, ON, Canada, 4 University of Western Ontario.
1222. Open Label Trial of Oral Treprostinil in Patients with Systemic
Sclerosis and History of Digital Ulcers: Multiple Dose
Pharmacokinetics and Tolerability. Elena Schiopu 6 , Laura K.
Hummers 2 , Ami A. Shah 2 , Susan Walker 4 , Kristine Phillips 6 ,
James R. Seibold 5 , Fredrick M. Wigley 1 and Kristan Rollins 3 ,
1
Johns Hopkins University, Baltimore, MD, 2 Johns Hopkins
University, Baltimore, MD, 3 United Therapeutics, RTP, NC,
4
United Therapeutics, 5 University of Conneticut, Farmington, CT,
6
University of Michigan, Ann Arbor, MI.
1223. Outcomes in a Newly Diagnosed Population of Connective
Tissue Disease-Associated Pulmonary Arterial Hypertension
Patients from the REVEAL Registry. Lorinda Chung 4 , Lori
Parsons 1 , Paul M. Hassoun 2 , Michael McGoon 3 , David Badesch 6 ,
Dave P. Miller 1 , Mark R. Nicolls 5 and Roham T. Zamanian 5 ,
1
ICON Clinical Research, 2 Johns Hopkins University, 3 Mayo
Clinic, 4 Stanford Univ Medical Center, Palo Alto, CA, 5 Stanford
University, 6 University of Colorado.
1224. Patients with Systemic Sclerosis and Anti-Centromere
Antibodies Are Affected with Accelerated Atherosclerosis.
Annica Nordin 2 , Lena Björnådal 3 , Kerstin Jensen-Urstad 1
and Elisabet Svenungsson 4 , 1 Dept. of Clinical Physiology,
Södersjukhuset, Karolinska Institutet, Sweden, 2 Dept. of
Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm,
Sweden, 3 Dept. of Medicine, Rheumatology Unit, Karolinska
Institutet, Sweden, Sweden, 4 Dept. of Medicine, Rheumatology
Unit, Karolinska Institutet, Sweden.
224
2010 Program Book